[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594626":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":33,"centralContacts":37,"locations":45,"responsibleParty":97,"collaborators":25,"id":99,"slug":100,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":101,"sex":107,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":25,"studyType":113,"phases":114,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":48,"whyStopped":25,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},{"fullName":5,"class":6},"Erasca, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ERAS-4001 Monotherapy Dose Optimization.","EXPERIMENTAL","Escalating doses of ERAS-4001 administered orally.",[13],"Drug: ERAS-4001",{"label":15,"type":10,"description":16,"interventionNames":17},"ERAS-4001 Combination Dose Optimization","ERAS-4001 administered orally with another investigational agent.",[18],"Drug: ERAS-4001 in combination",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","ERAS-4001","ERAS-4001 Administered orally",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"ERAS-4001 in combination","ERAS-4001 Administered orally and in combination with either Keytruda (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration.",[15],[31,32],"Keytruda (pembrolizumab)","Vectibix (panitumumab)",[34],{"name":35,"affiliation":5,"role":36},"Gerri Lee","STUDY_DIRECTOR",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":25,"email":42},"Erasca Clinical Team","CONTACT","+1-858-465-6511","clinicaltrials@erasca.com",{"name":44,"role":40,"phone":25,"phoneExt":25,"email":25},"Les Brail, Study Director, PhD",[46,60,70,79,87],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":25},"Sarah Cannon Research Institute (SCRI) Oncology Partners","RECRUITING","Nashville","Tennessee","32703","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-86.78444,36.16589,{"lat":58,"lon":57},{"facility":61,"status":48,"city":62,"state":63,"zip":64,"country":52,"countryCode":53,"cosmosGeoPoint":65,"geoPoint":69,"contacts":25},"The University of Texas MD Anderson Cancer Center","Houston","Texas","77030",{"type":55,"coordinates":66},[67,68],-95.36327,29.76328,{"lat":68,"lon":67},{"facility":71,"status":48,"city":72,"state":63,"zip":73,"country":52,"countryCode":53,"cosmosGeoPoint":74,"geoPoint":78,"contacts":25},"NEXT Oncology","Irving","75039",{"type":55,"coordinates":75},[76,77],-96.94889,32.81402,{"lat":77,"lon":76},{"facility":71,"status":48,"city":80,"state":63,"zip":81,"country":52,"countryCode":53,"cosmosGeoPoint":82,"geoPoint":86,"contacts":25},"San Antonio","78229",{"type":55,"coordinates":83},[84,85],-98.49363,29.42412,{"lat":85,"lon":84},{"facility":88,"status":48,"city":89,"state":90,"zip":91,"country":52,"countryCode":53,"cosmosGeoPoint":92,"geoPoint":96,"contacts":25},"Fred Hutchinson Cancer Center","Seattle","Washington","98109",{"type":55,"coordinates":93},[94,95],-122.33207,47.60621,{"lat":95,"lon":94},{"type":98,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100594626","phase-1-a-study-of-eras-4001-in-patients-with-advanced-or-metastatic-solid-tumors-100594626",false,"NCT07021898","A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.","A Phase 1 First-in-Human Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-4001 Monotherapy and in Combination in Patients With Advanced Solid Tumors","BOREALIS-1","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Willing and able to give written informed consent\n* Pathological documentation of tumor type and mutation prior to the first dose of study drug(s)\n* There is no available standard systemic therapy available for the patient's tumor histology and\u002For molecular biomarker profile; or standard therapy is intolerable, not effective, or not accessible; or patient has refused standard therapy\n* Able to swallow oral medication\n* Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1\n* Adequate cardiovascular, hematological, liver, and renal function\n* Willing to comply with all protocol-required visits, assessments, and procedures\n\nExclusion Criteria:\n\n* Previous treatment with a RAS inhibitor\n* Is currently receiving another study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of ERAS-4001\n* Received prior palliative radiation within 14 days of Cycle 1, Day 1\n* Have primary central nervous system (CNS) tumors\n* Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption\n* Have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs\n* Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial","ALL","18 Years","99 Years",{"count":111,"type":112},200,"ESTIMATED","INTERVENTIONAL",[115],"PHASE1","The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations. ERAS-4001 will be given alone or in combination with other treatments.",[118],"Metastatic Solid Tumors",[120,121,122,123,124,125,126,127,128,129,130],"Solid Tumor","Advanced Solid Tumor","Solid malignancies","Targeted therapy","Molecular alterations","pembrolizumab","Keytruda","panitumumab","Vectibix","Metastatic solid tumor","Neoplasms","2025-12-02",{"date":133,"type":134},"2025-12-03","ACTUAL",{"date":136,"type":134},"2025-08-06",{"date":138,"type":112},"2028-12",{"name":5,"class":6},5]